Gene therapy hope for ALS patients in early trial
Disease control
Not yet recruiting
This early-stage trial is testing a new gene therapy called SNUG01 for people with ALS, a disease that damages nerves controlling movement. The study will involve 21 adults and aims to check if the treatment is safe and tolerable. Researchers will also look for early signs that i…
Phase: PHASE1, PHASE2 • Sponsor: SineuGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC